Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report

被引：14
|
作者：
Su, Po-Lan [1 ]
Lin, Chien-Yu [1 ]
Chen, Yi-Lin [2 ]
Chen, Wan-Li [2 ]
Lin, Chien-Chung [1 ,3 ,4 ]
Su, Wu-Chou [3 ,5 ,6 ,7 ]
机构：
[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Inst Clin Med, Coll Med, Tainan, Taiwan
[4] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan
[5] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Oncol, Tainan, Taiwan
[6] Natl Cheng Kung Univ, Ctr Appl Nanomed, Tainan, Taiwan
[7] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Oncol, 138 Shengli Rd, Tainan 704, Taiwan
来源：
JTO CLINICAL AND RESEARCH REPORTS | 2021年 / 2卷 / 08期
关键词：
BRAF K601E mutation; Adenocarcinoma; Dab-rafenib; Trametinib; Case report; TARGETED THERAPY; CANCER;
D O I：
10.1016/j.jtocrr.2021.100202
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC with a BRAF K601E mutation, a class II BRAF mutation, who had a durable response to targeted therapy with combined dabrafenib and trametinib.(c) 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report
    Zhang, Qun
    Li, Li
    Qian, Xiaoping
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [42] Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance
    Xiong, Jin
    Xia, Lei
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [43] Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report
    Orciuolo, Corrado
    Cappuzzo, Federico
    Landi, Lorenza
    Resuli, Blerina
    Carpano, Silvia
    Vidiri, Antonello
    Buglioni, Simonetta
    Mandoj, Chiara
    Ciliberto, Gennaro
    Minuti, Gabriele
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (08):
  • [44] Cetuximab and Dabrafenib Plus Trametinib for Untreated Colonic Metastasis of BRAFV600E Mutant Primary Lung Adenocarcinoma with Signet Ring Cell Features: An Interesting and Rare Case Report
    Jiang, Shujun
    Wu, Yanran
    Wei, Wenjie
    Wang, Zi
    Wang, Qi
    ONCOTARGETS AND THERAPY, 2022, 15 : 1057 - 1062
  • [45] Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
    Yuta Adachi
    Naohiro Yanagimura
    Chiaki Suzuki
    Sakiko Ootani
    Azusa Tanimoto
    Akihiro Nishiyama
    Kaname Yamashita
    Koushiro Ohtsubo
    Shinji Takeuchi
    Seiji Yano
    BMC Cancer, 20
  • [46] BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report
    Sasaki, Makiko
    Shimura, Takaya
    Nishie, Hirotada
    Kuroyanagi, Keita
    Kanno, Takuya
    Fukusada, Shigeki
    Sugimura, Naomi
    Mizuno, Yusuke
    Nukui, Takayuki
    Uno, Konomu
    Kojima, Yuki
    Nishigaki, Ruriko
    Tanaka, Mamoru
    Ozeki, Keiji
    Kubota, Eiji
    Kataoka, Hiromi
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (07)
  • [47] Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
    Adachi, Yuta
    Yanagimura, Naohiro
    Suzuki, Chiaki
    Ootani, Sakiko
    Tanimoto, Azusa
    Nishiyama, Akihiro
    Yamashita, Kaname
    Ohtsubo, Koushiro
    Takeuchi, Shinji
    Yano, Seiji
    BMC CANCER, 2020, 20 (01)
  • [48] Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
    Chen, Xuesong
    Zha, Wangjian
    Su, Mei
    Meng, Nan
    Cao, Shuliang
    Niu, Beifang
    Qi, Xu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [49] Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
    Xu, Huanhuan
    Liang, Qi
    Xu, Xian
    Tan, Shanyue
    Wang, Sumeng
    Liu, Yiqian
    Liu, Lingxiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [50] EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature
    Zeng, Ran
    Luo, Lifeng
    Sun, Xianwen
    Bao, Zhiyao
    Du, Wei
    Dai, Ranran
    Tang, Wei
    Gao, Beili
    Xiang, Yi
    CANCER DRUG RESISTANCE, 2021, 4 (04) : 1019 - 1027
12345